# Independent evidence and requirements review

**Reviewer:** safety/regulation workstream agent, reviewing the lead-authored [report](../report.md), [product brief](../product-brief.md) and [validation protocol](validation-and-rfq-protocol.md). **Date: 17 October 2026.** The reviewer did **not** treat review of their own safety memo as independent assurance. This is an evidence/consistency review, not legal approval, medical validation or a completed formulation assessment. A different workstream reviews the numerical model.

## Verdict

**Pass after substantive corrections; final publication checks remain with the lead.** The lead recommendation is appropriately conditional and meets the substantive assignment: three alternative/staged launch architectures, a one-SKU minimum viable range, common-core versus multiple-formula trade-offs, can/bottle comparisons, a tagged provisional brief, low-cost validation, and independent CBD choices. No material error was found in the reviewed report's caffeine-concentration arithmetic, scientific-transfer framing or distinction between a favourable CBD supplement safety opinion and beverage authorization.

The first draft contained two product URLs unsupported by the source register and an unverified VYBES closure description. The recheck confirmed these were corrected. The original findings below are retained for an audit trail; their current status is recorded at the end.

## Required corrections in the reviewed draft

| ID | Finding | Required change | Verification |
|---|---|---|---|
| ER01 | The report's SLY DREAM row links to `drinksly.com/products/dream-orange-cream`, while PB17 records a different manufacturer domain/path. The report link was inaccessible in this check. | Replace with the exact verified PB17 URL: [DREAM Orange Cream](https://drinkonthesly.com/products/sly%E2%84%A2-dream-orange-cream). Do not characterize the inaccessible address as a confirmed 404; that was not established. | Opened the manufacturer page on 17 October 2026: it identifies 12oz, Orange Cream, January 2026 flavour release, melatonin and 8/12/24-packs. No efficacy inference is justified. |
| ER02 | The report's Gatorade launch row uses an unverified `gatorade-unveils-new-lower-sugar-formula...` slug, while PB22 records the actual release. The draft URL was inaccessible in this check. | Replace with [PepsiCo's Gatorade Lower Sugar release](https://www.pepsico.com/en/newsroom/press-releases/2026/gatorade-lower-sugar-brings-a-new-era-of-hydration-with-no-artificial-flavors-sweeteners-or-colors). | Opened 17 October 2026: dated 4 March 2026; describes nationwide availability and 12/20/28fl oz bottles. Exact 12oz nutrition remains supported by the separate SKU evidence, not transferred from a larger size. |
| ER03 | VYBES is described as having a “resealable-looking screw closure,” but the benchmark dataset explicitly records current closure/material as uninspected/unknown. | Remove that description or independently inspect and document the current 12oz closure. Keep general screw-cap-versus-crown-cap bottle comparisons separate from an unverified exact SKU. | [Current VYBES SKU text](https://idrinkvybes.com/products/strawberry-lavender) confirms bottle/12oz/still and nutrition, but the extracted text does not establish closure construction. No old 14oz pack inference should be carried forward. |
| ER04 | Many joins omit normal spaces: examples include “with330,” “use250,” “US12 fl oz,” “1hero,” and “atCZK39.50.” This substantially reduces readability in a founder-facing document. | Restore spaces between words/numbers and units, especially report tables and comparisons. Preserve values and source IDs. | Direct reading of the report and brief; editorial issue rather than an underlying evidence error. |

## Checks that passed

- **Format discipline:** all eleven dataset benchmarks are identified as finished cans or bottles, including the separate bottled FREE shot. The report excludes consumer powders, pouches, concentrates and other nonqualifying formats. Ingredient studies are not treated as product benchmarks. An unavailable Daytrip page is explicitly not counted as current sold-product traction.
- **Recent-event scope and commercial denominators:** product launches, retailer access, brand-reported segment rankings and measured sales are distinguished. Bloom's first-year energy-line retail sales are not assigned to one flavour, its supplements or a calendar year. Hiyo's cases are not converted into cans or revenue. Neutonic's current online formula and new retail assortment remain distinguished. VYBES' 12oz version is distinguished from the prior 14oz bottle.
- **Strategy does not presume breadth:** A and B are genuine alternative first launches; C is staged and conditional. Focus/energy is treated as a potential shared occasion, with no automatic higher-caffeine tier. An evening drink and dedicated sleep product are not conflated. Secondary gut/hydration/recovery opportunities are considered then deferred for distinct demand/process reasons.
- **Dose and scientific transfer:** 50 mg/0.330 l = 151.5 mg/l and 60 mg/0.250 l = 240 mg/l. The report does not treat a 40–60mg concept window as a cleared dose or proven productivity benefit. Theanine capsule findings are not presented as exact RTD efficacy; the lack of a caffeine-only comparator is acknowledged. The brief makes caffeine source, tolerances, cumulative intake and label wording unresolved.
- **Safety of combined use:** neither the range nor subscription is a mandatory daily system. Background caffeine and repeated nutrient exposure need assessment; an evening drink is not claimed to reverse caffeine. Single serving and resealability are not presented as overdose prevention. No completed combined-use test is invented.
- **CBD independence:** primary range is CBD-free, with no-CBD, later-variant and distinct-SKU options compared. Demand, efficacy, sourcing, food-use authorization, claims, safety, cost and brand complexity remain separate. The September 2026 specific MCT supplement opinion is not generalized to an aqueous drink, and the 150mg sublingual insomnia study is not generalized to a social can. No supplier is declared qualified, cost invented, or THC-led extension recommended.
- **Brief and validation discipline:** occasion, size, sweetness, calories, carbonation, ingredients/dose, price, packs, subscription, production and shelf life carry explicit unresolved gates. The nine-month shelf-life aspiration and 26-week model selling window are not reported as test results. Customer counts and research protocol are proposals, not completed interviews. No contact or purchase is implied.

## Resolution recheck

- **ER01 resolved:** report now uses the verified PB17 SLY URL.
- **ER02 resolved:** report now uses the verified PB22 PepsiCo release URL.
- **ER03 resolved:** report now says current VYBES closure/resealability is unverified, consistent with the dataset.
- **ER04 substantially resolved:** spacing was improved throughout. Final editorial sweep was requested for residual `atCZK` and `flavourJan` joins; neither changes an evidence conclusion.
- The brief now explicitly identifies 40–60 mg in 250 ml as 160–240 mg/l and prices its tested single can as 250 ml. Both clarifications are accurate and preserve the unresolved formulation/claims gates.
- The integrated source register now contains **69 unique source IDs**. Automated extraction found **no unregistered external URLs in the report**. This confirms registration, not universal external-page availability.

## Publication checks still owned by the lead

At the initial snapshot, the integrated `sources.csv` and `supporting/review-and-publication-checks.md` were not yet present; integration was explicitly in progress. The source register was subsequently verified as above. The publication-check file was still pending at recheck: ensure its relative link resolves before publishing. The product dataset parsed as eleven data records; its source file parsed as twenty-four records. No literal escaped-newline defect was found.

The lead should record ER01–ER04 resolutions in the publication-check file and verify committed content remotely. This review does not certify final repository publication, all external links, supplier capability, scientific efficacy or lawful sale of any proposed formula.
